menu search

Springworks therapeutics reports third quarter 2023 financial results and recent business highlights

– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 – – On track to report topline d...

November 2, 2023, 10:30 am

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting

– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...

November 1, 2023, 10:30 am

Rambus inc. (rmbs) q3 2023 earnings call transcript

Rambus Inc. (NASDAQ:RMBS ) Q3 2023 Earnings Conference Call October 30, 2023 5:00 PM ET Company Participants Desmond Lynch - Senior Vice President & C...

October 30, 2023, 10:38 pm

Chf icymi: swiss national bank to scrap interest paid on minimum reserves (ecb to follow?)

Justin had the Swiss National Bank news as it hit:SNB announces changes to remuneration of sight depositsIn Switzerland, from December 1:sight deposit...

October 30, 2023, 9:39 pm

Power hero corporation strengthens partnership with arrow electronics

Power Hero is passionate about clean energy and making it possible for everyone – especially in urban areas – to own an electric vehicle LA VERNE,...

October 30, 2023, 1:35 pm

Apollomics announces report of activity of vebreltinib in glioblastoma multiforme (gbm) with ptprz-met fusion

FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Ins...

October 26, 2023, 12:50 pm

Ambrx: next-generation antibody-drug conjugates, buying the dip after esmo data

Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 esmo data r...

October 24, 2023, 11:23 am

Merck & co. inc. (mrk) merck & co. announced collaboration with daiichi sankyo and esmo investor event (transcript)

Merck & Co. Inc. (NYSE:MRK ) October 22, 2023 1:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dr. Dean Li - President, Merck Research Labs E...

October 23, 2023, 11:32 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023

– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ca...

October 22, 2023, 8:25 am

Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...

October 21, 2023, 3:31 pm

Precede biosciences unveils groundbreaking clinical data for its pioneering liquid biopsy platform at esmo 2023 and simultaneously publishes in nature medicine

Pivotal findings stem from Precede’s first-in-class platform in collaboration with Dana-Farber Cancer Institute Results underscore the immense poten...

October 21, 2023, 8:25 am

Maia biotechnology to present preliminary safety and efficacy data from thio-101 phase 2 clinical trial at european society for medical oncology congress 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at...

October 19, 2023, 8:35 am

Predicine announces six studies showcasing mrd and liquid biopsy innovations at esmo 2023

HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for ...

October 17, 2023, 5:58 pm

Oric pharmaceuticals to present initial phase 1b clinical data for oric 114 in egfr/her2 exon 20 mutated nsclc at the european society of medical oncology (esmo) congress 2023

Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and p...

October 17, 2023, 4:30 pm

Apollomics announces presentations of vebreltinib data at esmo 2023

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical co...

October 16, 2023, 10:55 pm


Search within

Pages Search Results: